KEY INVESTMENT HIGHLIGHTS

Value Proposition

  • Combining one of the world's most innovative drug discovery platforms with development of novel, best-in-class therapies

 

Broadly Experienced Management Team

  • Extensive expertise in drug discovery and development in large opportunity markets in oncology and CNS

  • Deep understanding of ion channel physiology and CNS drug design

 

Robust Clinical Development Programs

  • Lead development program BNC210 is a negative allosteric modulator alpha 7 nicotinic acetylcholine receptor

BNC210 made strong progress in the clinic reporting positive Phase 2 clinical trial results in a Generalized Anxiety Disorder (GAD) patient population and the initiation of a Phase 2 clinical trial in patients with Post-Traumatic Stress Disorder (PTSD) 

  • BNC101 is a first-in-class anti-LGR5 antibody targeting cancer stem cells and continued to make progress during the year. In particular, the BNC101 Phase 1 clinical trial in patients with advanced metastatic colon cancer reached its recommended Phase 2 dose level of 15mg/kg without evidence of dose limiting toxicities or other significant safety issues. With identification of the recommended Phase 2 dose level, the Company initiated enrolment of the final expansion cohort of the study. 

  • Collaboration between Peter MacCallum Cancer Centre and Olivia Newton-John Cancer Wellness & Research Centre (ONJ Centre) received $2.25M grant to fund BNC105 trial in combination with Keytruda, a checkpoint inhibitor developed by MSD 


Three Proprietary Technology Platforms 

  • Multicore®: suite of integrated pharmacophore modelling and synthetic methods for generating chemical diversity enabling rapid drug candidate identification
  • ionX®:  integrated platform technologies that serve as the foundation of Bionomics' CNS drug discovery and development activities


Strong Cash Position

  • Solid balance sheet

  • Cash balance of AU$42.87M (as of 30 June 2017) to support robust clinical development programs

  • US$10M Merck milestone triggered as a candidate entered a Phase 1 clinical trial as part of ongoing collaboration for treatment of cognitive dysfunction associated with Alzheimer's disease

  • Market Cap: AU$219M (as at 17 August 2017)